Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/28184
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000 |
Author: | Mutnick, A. Biedenbach, D. Turnidge, J. Jones, R. |
Citation: | Diagnostic Microbiology and Infectious Disease, 2002; 43(1):65-73 |
Publisher: | Elsevier Science Inc |
Issue Date: | 2002 |
ISSN: | 0732-8893 1879-0070 |
Statement of Responsibility: | Alan H. Mutnick, Douglas J. Biedenbach, John D. Turnidge and Ronald N. Jones |
Abstract: | Resistance (R) among Gram-positive cocci has escalated in the last two decades to levels necessitating the development and use in the newer drug classes, oxazolidinones (linezolid) and streptogramins (quinupristin/dalfopristin [Q/D]). The SENTRY Antimicrobial Surveillance Program has monitored these classes before, during and after their release by various regulatory agencies. Over 30,000 Gram-positive strains were tested against >30 drugs by reference broth microdilution methods between 1998-2000 in four geographic regions (Asia-Western Pacific [APAC], Europe [EU], Latin America [LA], North America [NA]). The tested strains were 23,188 staphylococci; 5,103 enterococci and 2,045 streptococci. Among staphylococci, linezolid was active against all isolates (MICs, < or =4 microg/ml) regardless of susceptibility patterns of other antimicrobial agents. Similar results were noted for vancomycin (includes one VISA from Hong Kong), teicoplanin, and Q/D (<1% R). Gatifloxacin had the widest spectrum among fluoroquinolones (FQ) against Staphylococcus aureus (1.5-9.2% R) and coagulase-negative staphylococci (0.8-4.0%). Linezolid was also active against all enterococci (MIC50 and (90,) 2 microg/ml). Q/D was active against only 75.3% of vancomycin-resistant enterococci (VRE). The VRE rate was highest in NA (12.4%) > EU (3.2%) > LA (1.6%) > APAC (1.3%). Among streptococci, linezolid was consistently active (MIC(90,) 1 microg/ml) as were the glycopeptides and Q/D. Variable penicillin-R (MIC, > or = 2 microg/ml) was observed among regions: EU (32.5%) > APAC (15.1%) > LA (13.8%) > NA (9.6%), and macrolide-R was higher in EU (40.3%). Ciprofloxacin-R at > or =4 microg/ml in streptococcal strains was noted world wide highest in viridans group streptococci (18.4-25.6%). Linezolid remained active (MIC, < or =4 microg/ml) against all Gram-positive species strains tested in the SENTRY Program (1998-2000). Q/D, glycopeptides and newer FQ compounds were generally less effective in vitro. It remains a prudent practice to continue surveillance programs to detect emerging resistance patterns and recognize significant regional variations in the oxazolidinone susceptibilities. |
Keywords: | Humans Gram-Negative Bacteria Gram-Positive Bacteria Acetamides Oxazolidinones Anti-Bacterial Agents Microbial Sensitivity Tests Drug Resistance, Bacterial Cell Division Substrate Specificity Time Factors Americas Asia Europe Linezolid |
Description: | Copyright © 2002 Elsevier Science Inc. All rights reserved. |
DOI: | 10.1016/S0732-8893(02)00371-1 |
Description (link): | http://www.elsevier.com/wps/find/journaldescription.cws_home/505759/description#description |
Published version: | http://dx.doi.org/10.1016/s0732-8893(02)00371-1 |
Appears in Collections: | Aurora harvest 6 Molecular and Biomedical Science publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.